Latest Biotech News

Oricell Therapeutics said it raised more than $100 million in a pre-IPO round to support development of Ori-C101, a GPC3-targeted autologous CAR-T aimed at hepatocellular carcinoma. The company...

Roche is expanding its cancer modality bets with a new pact that merges antibody-drug conjugation and targeted protein degradation. In a collaboration with C4 Therapeutics, Roche agreed to pay $20...

BIOCENTURY reported that FDA is shifting away from a punitive structure under the “America First” PDUFA framework and toward a reward-based model. The change would reduce first-in-human-related...

Biopharma deal activity surged as March closed with a flurry of large transactions, according to Jefferies’ M&A scorecard coverage. The report said biopharma companies completed seven deals of...

Lilly said it launched Foundayo, its oral obesity pill, pushing the oral GLP-1 race into a new phase against Novo Nordisk’s Wegovy tablet. The company won FDA approval for Foundayo last week, and...

Waters said its BD Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay received 510(k) clearance from the FDA. The company positioned at-home self-collection as a way to improve access to...

The FDA issued a warning letter to Medline over issues with its Namic brand angiographic control syringes and manifolds used for radiographic contrast media administration. The agency identified...

Researchers reported mechanistic cancer biology implicating NAT10 in both chemotherapy resistance and immune evasion in gastric cancer. The findings, published in Cell Death Discovery, describe...

Stipple Bio emerged from stealth with a $100 million Series A round to advance STP-100, an antibody-drug conjugate designed to prevent off-target toxicity. The company says STP-100 uses...

Researchers reported that genome-wide methylome profiling of circulating cell-free DNA can predict outcomes in castration-resistant prostate cancer. The study described a new approach designed to...

Oricell Therapeutics, the Shanghai-based cell therapy developer, raised $100 million in its final pre-IPO financing round as it advances a GPC3-targeted autologous CAR-T for hepatocellular...

Gilead exercised an option to license Kymera Therapeutics’ preclinical protein degrader KT-200, paying $45 million as the drugmaker builds out an oncology pipeline focused on targeted protein...

Biopharma finance activity picked up in Q1 2026, with total financings reaching $22.82 billion—up about 74% year over year—signaling a stronger start for public-market and late-stage funding. The...

The FDA denied Harrison.ai’s petition seeking a partial 510(k) exemption for certain diagnostic and detection AI devices. The agency’s decision maintains the existing premarket review pathway...

AbbVie sued the federal government over the 340B program, arguing the interpretation of the word “patient” in the program should be revisited. The filing comes as the 340B discount framework...

23andMe reported genetic associations tied to how patients respond to GLP-1 receptor agonists, identifying variants that map to pharmacodynamic target genes. In a Nature study, investigators...

Cure or control strategies for difficult cancers remained active as clinical-stage and translational programs pushed forward. In glioblastoma, GLORIA trial results combine an L-RNA aptamer...

Waters received FDA 510(k) clearance for its BD Onclarity HPV self-collection kit and assay, enabling an at-home screening workflow for high-risk HPV detection. The company said the cleared...

Seer said it will support the PRECISE-SG100K initiative by profiling plasma proteomes for roughly 10,000 participants using its Proteograph platform. The workflow will be combined with data from...

A surge in March dealmaking underlined expectations for 2026’s merger cycle, with analysts tracking seven transactions worth more than $1 billion in a 12-day period. The reported headline value...